Angiotech Pharmaceuticals

ANP-T

0.00
0.00 (0.00%)
This company is not ACTIVE.

Analysis and Opinions about ANP-T

Signal
Opinion
Expert
TOP PICK
TOP PICK
June 10, 2004
Surprised that it hasn't moved a little more recently. Should do very well on the royalties in the coated stent market. Trades at 15 X next year's earnings. Building a pipeline as well.
Show full opinionHide full opinion
Surprised that it hasn't moved a little more recently. Should do very well on the royalties in the coated stent market. Trades at 15 X next year's earnings. Building a pipeline as well.
WAIT
WAIT
June 7, 2004
Has had a pretty good pullback in the last little while. Their marketer, Boston Scientific, on the other hand has been doing very well. Earnings/revenue are coming in much better than expected but wait for a positive trend to be established.
Show full opinionHide full opinion
Has had a pretty good pullback in the last little while. Their marketer, Boston Scientific, on the other hand has been doing very well. Earnings/revenue are coming in much better than expected but wait for a positive trend to be established.
TOP PICK
TOP PICK
May 31, 2004
Coated stents is probably the biggest area in the medical arena. Have reported good data. Expects their royalty rates to go up this summer.
Show full opinionHide full opinion
Coated stents is probably the biggest area in the medical arena. Have reported good data. Expects their royalty rates to go up this summer.
WAIT
WAIT
May 27, 2004
Stents have shown dramatic improvements. Not in a hurry to add money to the sector they are in. A good indicator is to watch Boston Scientific in the US who is marketing their stents. If it goes to a new high, that would be the time to get in.
Show full opinionHide full opinion
Stents have shown dramatic improvements. Not in a hurry to add money to the sector they are in. A good indicator is to watch Boston Scientific in the US who is marketing their stents. If it goes to a new high, that would be the time to get in.
HOLD
HOLD
May 17, 2004
Johnson and Johnson have come back as a competitive threat on their stents. Long-term will be good. Multiple may be a bit rich.
Show full opinionHide full opinion
Johnson and Johnson have come back as a competitive threat on their stents. Long-term will be good. Multiple may be a bit rich.
BUY
BUY
May 6, 2004
With Boston Scientific handling sales, you should see a growth. A great story.
Show full opinionHide full opinion
With Boston Scientific handling sales, you should see a growth. A great story.
DON'T BUY
DON'T BUY
April 28, 2004
Was a great stock as a concept stock but when manufacturing starts, the stock falls apart. Model price of $22.
Show full opinionHide full opinion
Was a great stock as a concept stock but when manufacturing starts, the stock falls apart. Model price of $22.
BUY
BUY
April 27, 2004
Down a little bit, but still should make lots of money.
Show full opinionHide full opinion
Down a little bit, but still should make lots of money.
TOP PICK
TOP PICK
April 22, 2004
The numbers four Boston Scientific have been spectacular. They have a better delivery stent. Should have a 70% market share.
Show full opinionHide full opinion
The numbers four Boston Scientific have been spectacular. They have a better delivery stent. Should have a 70% market share.
TOP PICK
TOP PICK
April 20, 2004
Coated stents have done very well. Boston Scientific just reported that the stents captured 70% of the market and had $98 million in sales. Accelerating momentum. We'll probably earn $.80/.90 this year and double next year.
Show full opinionHide full opinion
Coated stents have done very well. Boston Scientific just reported that the stents captured 70% of the market and had $98 million in sales. Accelerating momentum. We'll probably earn $.80/.90 this year and double next year.
BUY
BUY
April 20, 2004
A great company and one of Canada's success stories in biotech's. Prefers playing this through Boston Scientific which has better valuation.
Show full opinionHide full opinion
A great company and one of Canada's success stories in biotech's. Prefers playing this through Boston Scientific which has better valuation.
BUY
BUY
April 13, 2004
A great product. Tremendously high margins. Should make some money. Growth will be slower than what it has been in the past.
Show full opinionHide full opinion
A great product. Tremendously high margins. Should make some money. Growth will be slower than what it has been in the past.
DON'T BUY
DON'T BUY
April 13, 2004
Has been a great stock but doesn't think there's any more news for it. Fully valued.
Show full opinionHide full opinion
Has been a great stock but doesn't think there's any more news for it. Fully valued.
DON'T BUY
DON'T BUY
March 24, 2004
Has a problem with intellectual properties in biotech companies and competition, which in their case is Johnson and Johnson.
Show full opinionHide full opinion
Has a problem with intellectual properties in biotech companies and competition, which in their case is Johnson and Johnson.
BUY
BUY
March 17, 2004
Had a good base and broke out in early 2003. It must not break down through $30, but otherwise a good stock. Stop loss of $27/28.
Show full opinionHide full opinion
Had a good base and broke out in early 2003. It must not break down through $30, but otherwise a good stock. Stop loss of $27/28.
Showing 76 to 90 of 140 entries